Abstract
This review presents an overview of the field of immunoliposome-mediated targeting of anticancer agents. First, problems that are encountered when immunoliposomes are used for systemic anticancer drug delivery and potential solutions are discussed. Second, an update is given of the in vivo results obtained with immunoliposomes in tumor models. Finally, new developments on the utilization of immunoliposomes for the treatment of cancer are highlighted.
| Original language | English |
|---|---|
| Pages (from-to) | 103-127 |
| Number of pages | 25 |
| Journal | Advanced Drug Delivery Reviews |
| Volume | 40 |
| Issue number | 1-2 |
| DOIs | |
| Publication status | Published - 10 Nov 1999 |
Keywords
- antibody
- antineoplastic agent
- carcinoembryonic antigen
- cytarabine
- doxorubicin
- floxuridine
- fluorouracil
- immunoliposome
- ligand
- macrogol
- methotrexate
- monoclonal antibody
- oligonucleotide
- prodrug
- cancer chemotherapy
- drug clearance
- drug delivery system
- drug release
- drug stability
- drug targeting
- drug transport
- encapsulation
- endothelium cell
- heat sensitivity
- human
- immunogenicity
- internalization
- squamous cell lung carcinoma
- membrane fusion
- metastasis
- nonhuman
- ovary cancer
- peritoneal cavity
- pH
- priority journal
- review
- solid malignant neoplasm
- stomach cancer
- tumor vascularization
